XML 138 R94.htm IDEA: XBRL DOCUMENT
v3.22.4

Principal alliances - Immuno-Oncology Agreement with Regeneron Pharmaceuticals, Inc. (Details) € in Millions, $ in Millions |  |  | 1 Months Ended | 12 Months Ended
--- | --- | --- | --- | ---
Sep. 30, 2021 USD ($) | Jul. 01, 2015 agreement | Jul. 31, 2022 EUR (€) | Jul. 31, 2022 USD ($) | Jun. 30, 2022 EUR (€) | Jun. 30, 2022 USD ($) | Dec. 31, 2022 EUR (€) | Dec. 31, 2022 USD ($) | Dec. 31, 2021 EUR (€) | Dec. 31, 2020 EUR (€) | Dec. 31, 2015 USD ($)
Disclosure of Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Other operating income/(expenses), net related to the Regeneron Alliance | € |  |  |  |  |  |  | € (1,231) |  | € (1,373) | € (926) |  |
Assets held for sale or exchange | € |  |  |  |  |  |  | 85 |  | € 89 | € 83 | [1] |
Regeneron Pharmaceuticals, INC |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Assets held for sale or exchange | € |  |  |  |  |  |  | 226 |  |  |  |  |
Regeneron Pharmaceuticals, INC | Immuno-oncology collaboration agreement |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Number of agreements signed | agreement |  | 2 |  |  |  |  |  |  |  |  |  |
Maximum additional profit-share, in percentage of Regeneron's quarterly profit (in percent) |  |  |  |  |  |  |  |  |  |  |  | 10.00%
Percentage of cumulative development costs reimbursed |  |  |  |  |  |  |  |  |  |  |  | 50.00%
Upfront payments for projects under collaboration agreements | $ |  |  |  |  |  |  |  | $ 900 |  |  |  |
Regular milestone payments for projects under collaboration agreements |  |  |  |  | € 96 | $ 100 |  | $ 100 |  |  |  |
Regeneron Pharmaceuticals, INC | Immuno-oncology collaboration agreement | Major Collaboration Agreement |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Upfront payments for projects under collaboration agreements |  |  | € 856 | $ 900 |  |  |  |  |  |  |  |
Royalty income percentage (percentage) |  |  | 11.00% | 11.00% |  |  |  |  |  |  |  |
Other operating income/(expenses), net related to the Regeneron Alliance | € |  |  |  |  |  |  | 111 |  |  |  |  |
Proceeds from collaboration agreements | € |  |  |  |  |  |  | € 967 |  |  |  |  |
Regeneron Pharmaceuticals, INC | Immuno-oncology collaboration agreement | Development of cemiplimab (REGN2810) |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Prior development budget in total | $ |  |  |  |  |  |  |  |  |  |  |  | $ 1,640
Contractual agreement for anti-programmed cell death protein |  |  |  |  |  |  |  |  |  |  |  | 5000.00%
Maximum additional funding for PD1 - part of each company | $ | $ 1,840 |  |  |  |  |  |  |  |  |  |  | $ 820
PD1 sales milestone payment from Sanofi | $ |  |  |  |  |  |  |  |  |  |  |  | 375
Minimum sales of PD1 in 12-month period to be achieved for milestone payment | $ |  |  |  |  |  |  |  |  |  |  |  | $ 2,000
[1] | Includes the impacts of the IFRIC final agenda decisions of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April 2021 on the attribution of benefits to periods of service, as described in Note A.2.1. to the consolidated financial statements for the year ended December 31, 2021.

X
- Definition The amount of non-current assets or disposal groups classified as held for sale. [Refer: Disposal groups classified as held for sale [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 5 -IssueDate 2021-01-01 -Paragraph 38 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2021-en-r&anchor=para_38&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of operating income (expense) that the entity does not separately disclose in the same statement or note. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2021-01-01 -Paragraph 85 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_85&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_OtherOperatingIncomeExpense
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Anti programmed cell death protein 1 sales milestone payment. + References No definition available. + Details
Name: | sny_AntiProgrammedCellDeathProtein1SalesMilestonePayment
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Contractual Agreement For Anti-programmed Cell Death Protein1 + References No definition available. + Details
Name: | sny_ContractualAgreementForAntiProgrammedCellDeathProtein1
Namespace Prefix: | sny_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Disclosure of Principal Alliances [Line Items] + References No definition available. + Details
Name: | sny_DisclosureOfPrincipalAlliancesLineItems
Namespace Prefix: | sny_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Maximum additional funding for anti programmed cell death protein 1 part of each company. + References No definition available. + Details
Name: | sny_MaximumAdditionalFundingForAntiProgrammedCellDeathProtein1PartOfEachCompany
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Minimum sales of anti programmed cell death protein 1 in twelve month period to be achieved for milestone payment. + References No definition available. + Details
Name: | sny_MinimumSalesOfAntiProgrammedCellDeathProtein1InTwelveMonthPeriodToBeAchievedForMilestonePayment
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number Of Agreements Signed + References No definition available. + Details
Name: | sny_NumberOfAgreementsSigned
Namespace Prefix: | sny_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of cumulative development costs reimbursed. + References No definition available. + Details
Name: | sny_PercentageOfCumulativeDevelopmentCostsReimbursed
Namespace Prefix: | sny_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of profit share on counter parties profit. + References No definition available. + Details
Name: | sny_PercentageOfProfitShareOnCounterpartiesProfit
Namespace Prefix: | sny_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Prior development budget. + References No definition available. + Details
Name: | sny_PriorDevelopmentBudget
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Proceeds From Collaboration Agreements + References No definition available. + Details
Name: | sny_ProceedsFromCollaborationAgreements
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Regular Milestone Payments For Projects Under Collaboration Agreements + References No definition available. + Details
Name: | sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Royalty Income, Percentage + References No definition available. + Details
Name: | sny_RoyaltyIncomePercentage
Namespace Prefix: | sny_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront Payments For Projects Under Collaboration Agreements + References No definition available. + Details
Name: | sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_RegeneronPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_PrincipalAlliancesAxis=sny_ImmunoOncologyCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=sny_MajorCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_TypesOfAgreementAxis=sny_DevelopmentOfCemiplimabREGN2810Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |